Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies
- 9 March 2005
- journal article
- review article
- Published by Elsevier BV in Neuropharmacology
- Vol. 48 (8), 1154-1163
- https://doi.org/10.1016/j.neuropharm.2005.01.001
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Massive accumulation of N‐acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?Journal of Neurochemistry, 2004
- Decreased potassium channel IK1 and its regulator neurotrophin-3 (NT-3) in inflamed human bowelNeuroReport, 2003
- Immunomodulation by the Autonomic Nervous System: Therapeutic Approach for Cancer, Collagen Diseases, and Inflammatory Bowel DiseasesTherapeutic Apheresis, 2002
- Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in miceBritish Journal of Pharmacology, 2001
- Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamideEuropean Journal of Pharmacology, 2001
- Epidemiology, etiology, diagnostic evaluation, and treatment of low back painCurrent Opinion in Rheumatology, 2001
- Role of the endogenous cannabinoid system in the formalin test of persistent pain in the ratEuropean Journal of Pharmacology, 2000
- A Comparison of Osteopathic Spinal Manipulation with Standard Care for Patients with Low Back PainNew England Journal of Medicine, 1999
- Control of pain initiation by endogenous cannabinoidsNature, 1998
- Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in LeukocytesJournal of Biological Chemistry, 1997